Organization
Yale School of Medicine, New Haven, CT
3 abstracts
Abstract
Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.Org: Faculdade de Medicina da Universidade de São Paulo, Massachusetts General Hospital Cancer Center, Federal University of Minas Gerais (UFMG), Case Western Reserve University School of Medicine, Penn State University College of Medicine,
Abstract
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas Southwestern Medical Center, Dallas, TX, Stanford Cancer Center GI Surgical Oncology, Stanford, CA, Cedars-Sinai Cancer Institute, Los Angeles, CA, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).Org: Barbara Ann Karmanos Cancer Institute, Detroit, MI, Clinical Research at South Texas Accelerated Research Therapeutics (START), San Antonio, TX, Mary Crowley Cancer Research Center, Dallas, TX, Division of Hematology & Medical Oncology, Oregon Health and Science University, Portland, OR, University of Colorado - Anschutz Medical Campus, Aurora, CO,